<DOC>
	<DOCNO>NCT00245115</DOCNO>
	<brief_summary>RATIONALE : Giving colony-stimulating factor , G-CSF , certain chemotherapy drug , help stem cell move bone marrow blood collect . Treating stem cell collect patient 's blood bone marrow chemotherapy laboratory remove remain cancer cell . Chemotherapy radiation therapy give patient prepare bone marrow stem cell transplant . The treated stem cell return patient replace blood-forming cell destroy chemotherapy . PURPOSE : This clinical trial study well autologous peripheral stem cell bone marrow transplant use laboratory-treated cell work treat patient acute leukemia .</brief_summary>
	<brief_title>Autologous Peripheral Stem Cell Bone Marrow Transplant Using Laboratory-Treated Cells Treating Patients With Acute Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility ex vivo expand mafosfamide-purged CD34-positive cell autologous peripheral blood stem cell bone marrow transplantation patient acute leukemia . - Determine duration aplasia associate use ex vivo cytokine expand mafosfamide-purged cell patient treat regimen . - Determine , preliminarily , event-free survival patient treat regimen . OUTLINE : This pilot study . - Mobilization stem cell collection : Patients receive cyclophosphamide IV filgrastim ( G-CSF ) subcutaneously ( SC ) IV daily 7-14 day follow leukapheresis collect peripheral blood stem cell ( PBSCs ) . Some patient may also undergo bone marrow ( BM ) harvest sufficient PBSCs collect . Patients sufficient number stem cell BM ( 5 x 10^6 PBSC/kg 3 x 10^8 BM cells/kg ) proceed autologous PBSC transplantation ( PBSCT ) BM transplantation ( BMT ) . - CD34-positive cell selection mafosfamide purging : Collected PBSCs and/or BM treat laboratory isolate CD34-positive cell . A minimum 1 x 10^6 nucleated CD34-positive BM cells/kg 2 x 10^6 nucleated CD34-positive PBSCs/kg must available selection proceed mafosfamide-purging . The selected cell treat vitro mafosfamide purge remain leukemic cell . One third mafosfamide-purged cell cryopreserved future use 2/3 mafosfamide-purged cell proceed ex vivo expansion . - Ex vivo expansion : The remain CD34-positive mafosfamide-purged cell treat vitro stem cell factor , G-CSF , recombinant human thrombopoietin incubate 12-14 day . - Myeloablative therapy : Patients receive busulfan day -9 -6 cyclophosphamide day -5 -2 . - PBSCT BMT : Patients undergo autologous PBSCT BMT use CD34-positive mafosfamide-purged cryopreserved cell ex vivo expand CD34-positive mafosfamide-purged cell day 0 follow G-CSF SC IV daily blood count recover . After completion study treatment , patient follow periodically least 5 year . PROJECTED ACCRUAL : A total 25 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute leukemia meeting 1 follow criterion : Highrisk acute myeloid leukemia ( AML ) first complete remission ( CR ) match family donor available , include follow type : Secondary AML AML chromosome 5 7 abnormality AML trisomy 8 AML 6 ; 9 chromosomal translocation AML 11q23 chromosomal abnormality AML multiple complex chromosomal abnormality AML FAB M6 M7 AML second CR ( CR2 ) eligible HLAidentical sibling donor available Highrisk acute lymphoblastic leukemia ( ALL ) eligible HLAidentical sibling donor available , include follow type : Philadelphia chromosomepositive ALL ALL 11q23 chromosomal abnormality ALL CR2 Eligible willing undergo bone marrow transplantation No intermediate goodrisk acute leukemia CR1 PATIENT CHARACTERISTICS : Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Not pregnant Fertile patient must use effective contraception HIV negative Weight â‰¥ 10 kg No poor organ function PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
</DOC>